title: [Integration of drug treatment in the management concept of prostate cancer].
abstract: The drug treatment of prostate cancer was for many years based on androgen deprivation with luteinizing hormone-releasing hormone (LHRH) analogues.This treatment still represents the standard first line treatment for advanced prostate cancer. In cases of progression to metastatic castration-resistant prostate cancer (mCRPC) further treatment options used to be limited. Only the chemotherapy drug docetaxel could demonstrate a significant overall survival benefit. Within the last few years, however, five new treatments for patients with mCRCP have achieved significant results in large phase III trials. Interestingly they have different mechanisms of action: abiraterone is a testosterone synthesis inhibitor, enzalutamide is a novel antiandrogen, cabazitaxel is a cytotoxic drug, radium-223 is a radionuclide and sipuleucel-T an immunotherapy. Further new drugs are under investigation. The integration of these new treatment options as well as an optimal sequence and combination is the main focus of current research.
authors.affiliation: Abteilung medizinische Onkologie, Kantonsspital Graubünden, Loestr. 170, 7000, Chur, Schweiz, richard.cathomas@ksgr.ch.
authors.forename: R
authors.initials: R
authors.lastname: Cathomas
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D019275:Radiopharmaceuticals; D043823:Taxoids; D000077143:Docetaxel
references.citation: Lancet. 2011 Mar 5;377(9768):813-22
references.pmid: 21353695
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1596-605
references.pmid: 17404365
references.citation: Eur Urol. 2011 Apr;59(4):572-83
references.pmid: 21315502
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: Lancet. 2000 Apr 29;355(9214):1491-8
references.pmid: 10801170
references.citation: JAMA. 2005 Jul 13;294(2):238-44
references.pmid: 16014598
references.citation: Eur Urol. 2013 Aug;64(2):300-6
references.pmid: 23313031
references.citation: N Engl J Med. 2013 Apr 4;368(14):1314-25
references.pmid: 23550669
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Hematol Oncol Clin North Am. 2006 Aug;20(4):909-23
references.pmid: 16861122
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: Circulation. 2010 Feb 16;121(6):833-40
references.pmid: 20124128
references.citation: Ann Surg. 1942 Jun;115(6):1192-200
references.pmid: 17858048